Clinical Trials
183
14 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
N/A
Active, not recruiting
6
3.3%
Completed
96
52.5%
Enrolling By Invitation
2
1.1%
Not yet recruiting
6
3.3%
Recruiting
26
14.2%
Suspended
4
2.2%
Terminated
19
10.4%
Unknown
7
3.8%
Withdrawn
17
9.3%
No approval data available
- A UC Irvine and McLean Hospital study published in Nature Mental Health found that using biological and behavioral biomarkers to guide antidepressant selection improved response rates by nearly 67% compared to patients without favorable biomarker profiles. - Response rates reached 71.4% among patients with positive biomarkers for both sertraline and bupropion, versus 42.8% for those with no positive biomarkers. - The research represents one of the first efforts to test biomarker-guided antidepressant treatment selection in major depressive disorder, though the small sample size (fewer than 50 patients) limits immediate clinical applicability. - Researchers caution that costly functional MRI scans used in the study are not yet practical for routine clinical settings, but the findings lay groundwork for larger precision psychiatry trials.
- A prospective biomarker-guided trial found that patients with favorable biological markers for both sertraline and bupropion achieved a 71.4% response rate versus 42.9% for those with no positive markers, a nearly 67% improvement. - The study used functional MRI brain connectivity, cognitive reward sensitivity, and clinical profiles to predict treatment outcomes in major depressive disorder, though the primary matched-vs-unmatched drug comparison did not reach statistical significance. - Researchers caution that the small sample size (fewer than 50 patients) and high cost of fMRI scans mean the approach is not yet ready for routine clinical deployment. - The findings provide proof of concept that depression is biologically heterogeneous and that objective biomarkers may eventually guide personalized antidepressant selection, fast-tracking non-responders to alternative therapies.
- Mass General Brigham launches pioneering Phase 1 trial using patients' own reprogrammed stem cells to replace damaged dopamine neurons in Parkinson's disease, with three of six participants treated successfully. - The innovative treatment converts patients' blood cells into induced pluripotent stem cells (iPSCs), which are then transformed into dopamine neurons, eliminating the need for immunosuppression. - The FDA-approved trial, based on three decades of research at McLean Hospital, will monitor patients for 12 months to assess safety and potential improvements in Parkinson's symptoms.
